A recent review in Clinical Advances in Hematology & Oncology spotlights promising developments in gastrointestinal oncology — especially for colorectal and pancreatic cancers, where late-stage diagnoses have long limited options. Highlights include fruquintinib for refractory metastatic CRC, the tucatinib + trastuzumab combination for HER2-positive CRC, and expanded uses for trifluridine-tipiracil in combination regimens.
Trending
- The motor car has arrived in GI – are we still thinking horses?
- Why GI Can’t Ignore the Microbiome Revolution Any Longer
- Cyted raises $44m to propel US market expansion of its endoscopic capsule (Medical Device Network)
- Impact of Short Duration FODMAP Restriction on Breath Gases and Gastrointestinal Symptoms (Clinical & Translational Gastroenterology)
- Prior authorization panic (Politico)
- GLP-1 Use After Bariatric Surgery on the Rise (Medscape)
- Management Services Organizations: A growing strategy for physician groups (Medical Economics)
- Rideshare Cuts Colon Cancer Deaths, Saves Costs After Abnormal FIT, Study Finds (AJMC)
